RADIATION SAFETY OFFICER DESIGNATION

July 27, 2026

U.S. NRC Region III
2443 Warrenville Road
Suite 210
Lisle, Illinois 60532-4352

Re: Amendment to Add & Remove Authorized Users to
NRC Radioactive Material License (RML) 21-00299-04

Dear Sir/Madam,

VHS Sinai-Grace Hospital, Inc seeks to amend Radioactive Materials License #21-00299-04. The Authorized User has been approved by the Radiation Safety Committee. Supporting material is attached.

1. Please add **Ahmed Mohamed El-Sabbagh, M.D.**, as an Authorized User. We request approval for Dr. El-Sabbagh to have authorized use as applicable for the following:
    a. Any byproduct material permitted by 10 CFR 35.100
    b. Any byproduct material permitted by 10 CFR 35.200
    c. Any byproduct material permitted by 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
    d. Yttrium-90 permitted by 10 CFR 35.1000, Microspheres (BWXT Medical, Ltd., Model Therasphere glass microspheres), condition 6D on our RML

    We have enclosed a copy of NRC Radioactive Material License #21-26740-01 that attests to their training and experience and the Preceptor Attestation for Y-90 TheraSphere with documented cases.

2. Please add **Richard Krikorian, D.O.**, as an Authorized User. We request approval for Dr. Krikorian to have authorized use as applicable for the following:
    a. Any byproduct material permitted by 10 CFR 35.100
    b. Any byproduct material permitted by 10 CFR 35.200

    We have enclosed a copy of NRC Radioactive Material License #21-24652-01 that attests to their training and experience.

3. Please add **Victoria A. Swegles, D.O.**, as an Authorized User. We request approval for Dr. Swegles to have authorized use as applicable for the following:
    a. Any byproduct material permitted by 10 CFR 35.100
    b. Any byproduct material permitted by 10 CFR 35.200

    We have enclosed a copy of NRC Radioactive Material License #21-24652-01 that attests to their training and experience.

4. Please add **Foaz Kayali, M.D.**, as an Authorized User. We request approval for Dr. Kayali to have authorized use as applicable for the following:
    a. Any byproduct material permitted by 10 CFR 35.100
    b. Any byproduct material permitted by 10 CFR 35.200

c. Any byproduct material permitted by 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

We have enclosed a copy of NRC Radioactive Material License #21-04127-02 that attests to their training and experience.

5. Please add **Cheryl Grigorian, M.D.**, as an Authorized User. We request approval for Dr. Grigorian to have authorized use as applicable for the following:
   a. Any byproduct material permitted by 10 CFR 35.100
   b. Any byproduct material permitted by 10 CFR 35.200
   c. Any byproduct material permitted by 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

   We have enclosed a copy of NRC Radioactive Material License #21-04127-02 that attests to their training and experience.

6. Please remove Hani Abujudeh, M.D., as an Authorized User on our license.


7. Please remove Thomas Matthys, M.D., as an Authorized User on our license.

8. Please remove Daniel J. Walz, M.D., as an Authorized User on our license.

Enclosures: NRC RML #21-26740-01
NRC RML #21-24652-01
NRC RML #21-04127-02
Dr. El-Sabbagh Preceptor Attestation
Documented TheraSphere Patient Cases

Thank you for reviewing this amendment request.

Sincerely,



7/27/2026

Joel Rogers
RSO
VHS Sinai-Grace Hospital, Inc

Date

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 27

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated November 17, 2025,	4. Expiration Date: October 31, 2037
1. Henry Ford Health Genesys Hospital		
2. One Genesys Parkway Grand Blanc, MI 48439	3. License No.: 21-26740-01 is amended in its entirety to read as follows:	5. Docket No.: 030-34188 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Yttrium-90 permitted by 10 CFR 35.1000	D. Microspheres (BWXT Medical Ltd., Model TheraSphere)	D. 540 millicuries per vial and 2 curies total	D. For medical use in permanent manual brachytherapy using BWXT Medical Ltd. Model TheraSphere Y-90 Glass Microsphere System as permitted by 10 CFR 35.1000.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License No.: 21-26740-01

Amendment No. 27

Docket or Reference No.: 030-34188

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
E. Yttrium-90 permitted by 10 CFR 35.1000	E. Microspheres (Sirtex Wilmington, LLC, Model SIR-Spheres)	E. 540 millicuries per vial and 2 curies total	E. For medical use in permanent manual brachytherapy using Sirtex Medical Model SIR-Spheres microspheres and delivery system permitted by 10 CFR 35.1000.

UNITED STATES NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-26740-01	Docket or Reference No.: 030-34188
	Amendment No. 27	

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at One Genesys Parkway, Grand Blanc, Michigan, 48439.

11. The Radiation Safety Officer (RSO) for this license is Karl F. Kado, M.D.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)	Material and Use
Mohammed S. Ibrahim Alagha, M.D.	10 CFR 35.100,10 CFR 35.200
Steven D. Brooks, D.O.	10 CFR 35.100,10 CFR 35.200
Ahmed Mohamed El-Sabbagh, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
Roger L. Gonda, Jr., M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Khaled Hammoud, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
Reham Haroun, M.D.	10 CFR 35.1000 (limited to Yttrium-90 SIR-Spheres and TheraSpheres)
Karl F. Kado, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to oral administration of sodium iodide I-131)
Vikram Aroor Kinni, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Shehbaz Hasan Shaikh, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries),10 CFR 35.1000 (limited to Y-90 TheraSphere microspheres)

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-26740-01	Docket or Reference No.: 030-34188
	Amendment No. 27	

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

A. Letter dated April 22, 2022 (ML22116A075)
B. Letter dated May 11, 2022 (ML22132A052)
C. Letter dated January 12, 2023 (ML23017A103)
D. Letter dated January 30, 2023 (ML23033A062)
E. Letter dated July 2, 2024 (ML24205A225)
F. Letter dated July 30, 2024 (ML24214A055)
G. Letter dated November 17, 2025 (ML25321A455)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: February 3, 2026

By: _____
Laura B. Cender
Region 3

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with application dated April 26, 2021,	4. Expiration Date: October 31, 2036
1. VHS Huron Valley-Sinai Hospital, Inc. 2. 1 William Carls Dr. Commerce, MI 48382-2201	3. License No.: 21-24652-01 is renewed in its entirety to read as follows:	5. Docket No.: 030-29063 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-24652-01	Docket or Reference No.: 030-29063
	Amendment No. 40	

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at 1 William Carls Dr., Commerce, Michigan, 48382.

11. The Radiation Safety Officer (RSO) for this license is Victoria A. Swegles, D.O.

12. Licensed material shall only be used by, or under the supervision of:

    A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

    B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)	Material and Use
Richard Krikorian, D.O.	10 CFR 35.100,10 CFR 35.200
Victoria A. Swegles, D.O.	10 CFR 35.100,10 CFR 35.200

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-24652-01	Docket or Reference No.: 030-29063
	Amendment No. 40	

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

A. Application dated April 26, 2021 received October 21, 2021 (ML21295A204)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: October 25, 2021

By: Frank P. Tran Digitally signed by Frank P. Tran Date: 2021.10.25 15:21:39 -05'00'

Frank P. D. Tran
Region 3

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 112

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. VHS Harper-Hutzel Hospital, Inc.

2. 3990 John R. Street
Detroit, MI 48201

In accordance with letter dated September 25, 2025,

3. License No.: 21-04127-02 is amended in its entirety to read as follows:

4. Expiration Date: December 31, 2036

5. Docket No.: 030-02045
Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 3 curies total	C. For any use permitted by 10 CFR 35.300.
D. Yttrium-90 permitted by 10 CFR 35.1000	D. Microspheres (BWXT Medical, Ltd., Model TheraSphere glass microspheres)	D. 540 millicuries per vial; 2 curies total	D. For use in permanent manual brachytherapy using BWXT Medical, Ltd. Model TheraSphere Y-90 glass microsphere delivery system permitted by 10 CFR 35.1000.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License No.: 21-04127-02

Amendment No. 112

Docket or Reference No.: 030-02045

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
E. Yttrium-90 permitted by 10 CFR 35.1000	E. Microspheres (Sirtex Medical, Model SIR-Spheres resin microspheres)	E. 296 millicuries per vial; 2 curies total	E. For use in permanent manual brachytherapy using Sirtex Model SIR-Spheres SIROS device and SIR-Spheres Legacy device delivery systems permitted by 10 CFR 35.1000.

UNITED STATES NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-04127-02	Docket or Reference No.: 030-02045
	Amendment No. 112	

CONDITIONS

10. A. Licensed material may be used or stored at the licensee's facilities located at 3990 John R. St., Detroit, Michigan, 48201.

    B. Licensed material listed in Subitem Nos. 6.C. through 6.E. may also be used at the licensee's facilities located at 4100 John R. St., Detroit, Michigan 48201, in accordance with the "Joint Operating Agreement for Radiation Safety," dated May 19, 2021, as provided in application dated May 25, 2021 (ML21153A120).

    C. Licensed material listed in Subitem No. 6.B. may also be used at the licensee's facilities located at DMC Heart Hospital, 311 Mack Ave., Detroit, Michigan, 48201.

11. A. The Radiation Safety Officer (RSO) for this license is Joel Rogers, M.S.

    B. The Associate Radiation Safety Officer (ARSO) for this license is Shawn Pickett for 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 and 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres and TheraSphere).

12. A. Licensed material listed in Subitem Nos. 6.A. through 6.E. is only authorized for use by, or under the supervision of an authorized user as defined in 10 CFR 35.2.


    C. Individuals designated as authorized users for the use of licensed material listed in Subitem Nos. 6.D. through 6.E. shall meet the training and experience requirements as specified in letter dated October 6, 2017 (ML17279A898), and shall be designated in writing by the licensee's Radiation Safety Committee, Richard N. Joyrich, M.D., Chairman.

13. In accordance with letters dated October 30, 2007 (ML073050468) and May 9, 2017 (ML17198A547), the licensee may make changes to its radiation safety program, as it relates to the use of yttrium-90 as Theraspheres and SIR-Spheres.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 21-04127-02	Docket or Reference No.: 030-02045
	Amendment No. 112	

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated May 25, 2021 (ML21153A120)
B. Letter dated November 30, 2021 (ML21334A438)
D. Letter dated October 30, 2007 (ML073050468)
E. Letter dated May 9, 2017 (ML17198A547)
F. Letter dated October 2, 2017 (ML17279A898)
G. Letter dated October 14, 2021 (ML22041B534)
H. Letter dated January 10, 2025 (ML25021A034)
I. Letter dated April 8, 2025 (ML25099A265)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: December 23, 2025

By: _____
Laura B. Cender
Region 3

7/16/2026

RE: Supervised Hands-On Patient Case Experience for Dr. Ahmed M El-Sabbagh for the Medical Use of TheraSpheres® Yttrium-90 Glass Microspheres

To Whom It May Concern:

Dr. El-Sabbagh has successfully completed 3 # hands-on patient cases for the medical use of TheraSpheres® yttrium-90 (Y-90) glass microspheres under my supervision. Documentation for at least three (3) of the supervised hands-on patient cases for the medical use of TheraSpheres® Y-90 glass microspheres is attached.

I confirm that I am currently an Authorized User for TheraSpheres® Y-90 glass microspheres at DMC Harper Hospital, on State of MICHIAGN RML# 21-04127-02.

I believe Dr. El-Sabbagh has satisfactorily completed the training requirements in accordance with U.S. Nuclear Regulatory Commission's April 2021 Microsphere Brachytherapy Sources and Devices Guidance Section B Pathway to become an Authorized User for TheraSpheres® yttrium-90 glass microspheres.



Richard N. Joyrich, MD
Director, Nuclear Medicine
Department of Radiology
DMC, Harper Hospital

Enclosures

Documentation for supervised clinical use (min 3 cases)

First	Last	Institution	City State	Procedure	Date	Accession	MPI	Product
Ahmed Mohamed	El-Sabbagh	VHS Harper-Hutzel Hospital	Detroit, MI	Embolization of tumor	7/13/26	NM260003215	41356334	Therasphere
Ahmed Mohamed	El-Sabbagh	VHS Harper-Hutzel Hospital	Detroit, MI	Embolization of tumor	6/26/26	NM260002938	06261886	Therasphere
Ahmed Mohamed	El-Sabbagh	VHS Harper-Hutzel Hospital	Detroit, MI	Embolization of tumor	6/9/26	NM260002603	40707120	Therasphere
Gulcin	Altinok	VHS Harper-Hutzel Hospital	Detroit, MI	Embolization of tumor	7/13/26	NM260003215	41356334	Therasphere
Gulcin	Altinok	VHS Harper-Hutzel Hospital	Detroit, MI	Embolization of tumor	6/26/26	NM260002938	06261886	Therasphere
Gulcin	Altinok	VHS Harper-Hutzel Hospital	Detroit, MI	Embolization of tumor	6/9/26	NM260002603	40707120	Therasphere

From: Rogers, Joel
To: R3-DRSSMail Resource
Subject: [External_Sender] Amendment Request
Date: Monday, July 27, 2026 7:07:02 AM
Attachments: image001.png
image002.png
2026-07-Add-Remove AUs-RML#21-002990-04.pdf

Good morning,

Please see the attached amendment request.

Thank you,

Joel Rogers, MS, DABR
Medical Physicist
Regional Director,
Great Lakes
Phone: (313) 573-0490
LANDAUER®

Fluke
Health
Solutions

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message.